Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Oral Chaperone Therapy Migalastat for the Treatment of Fabry Disease: Potentials and Pitfalls of Real-World Data

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Comment on: "Cell Therapy for Heart Disease: Trial Sequential Analyses of Two Cochrane Reviews"

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The mitochondria in heart failure: a target for coenzyme Q10 therapy?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Application of cell-free DNA for genomic tumor profiling: a feasibility study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Paclitaxel is mainly eliminated by CYP2C8 in the liver. CYP2C8 is strongly inhibited by the clopidogrel metabolite acyl-β-D-glucuronide. To determine if this interaction has clinical relevance, we identified 48 patients treated with clopidogrel and paclitaxel using databases and a prescription register. Peripheral sensory neuropathy was retrospectively evaluated from medical charts and compared to that of 88 age- and sex-matched controls treated with paclitaxel and low-dose aspirin. By a cumulative dose of 1,500 mg paclitaxel, 35% of the patients had developed severe neuropathy. The overall hazard ratio between clopidogrel use and severe paclitaxel neuropathy was 1.7 (95% confidence interval, 0.9-3.0). Among those receiving a high-dose paclitaxel regimen, the hazard ratio was 2.3 (95% confidence interval, 1.1-4.5). Our study indicates that clopidogrel is associated with a clinically relevant increased risk of neuropathy in patients treated with high-dose paclitaxel.

Original languageEnglish
JournalClinical Pharmacology and Therapeutics
Volume102
Issue number3
Pages (from-to)547-553
Number of pages7
ISSN0009-9236
DOIs
Publication statusPublished - Sep 2017

    Research areas

  • Aged, Aspirin, Cytochrome P-450 CYP2C8, Dose-Response Relationship, Drug, Drug Interactions, Female, Humans, Liver, Male, Middle Aged, Paclitaxel, Peripheral Nervous System Diseases, Pharmacoepidemiology, Platelet Aggregation Inhibitors, Retrospective Studies, Severity of Illness Index, Ticlopidine, Journal Article

ID: 52073264